Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma

JAMA

Volumn 305, Issue 8, 2011, Pages 781-

  Pazo, Robert A ^a   Lao, Juan ^a   Lanzuela, Manuela ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PLACEBO; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PRACTICE; HUMAN; LETTER; LIVER CELL CARCINOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; BIOASSAY; DISEASE COURSE; LIVER TUMOR; NOTE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DOXORUBICIN; ENDPOINT DETERMINATION; HUMANS; LIVER NEOPLASMS; PROGNOSIS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 79951983380     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.159     Document Type: Letter

References (3)

1. Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxo-rubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010;304(19):2154-2160.
2. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist. 2006;11(7):790-800. (Pubitemid 44157567)
3. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.